title: [Comparative study between 10 and 20 mg of cetirizine in the symptomatic treatment of seasonal allergic rhinoconjunctivitis].
abstract: Our patients with seasonal allergic rhinoconjunctivitis usually present severe clinical symptoms. A single daily dose of cetirizine 10 mg might be insufficient for these patients. To investigate this hypothesis we compared clinical efficacy and adverse side effects between two daily doses of cetirizine, 10 and 20 mg. We designed a comparative open randomized study, including 38 patients, with hay fever sensitized to local pollens (grass, olive, parietaria judaica, chenopodium album, artemisia vulgaris and plantago lanceolata) diagnosed by clinical history and a positive skin prick test (wheal > 3 mm), 20 women and 18 men, aged 17 to 57 years (x: 31.32 +/- 9.73), living in the same geographic area. Randomly, after a week run in period, 21 subjects received a daily dose of cetirizine 10 mg during 2 weeks, and the other 17 received 10 mg twice a day. The symptomatic score used was based on: sneezes number, nasal itching, nasal secretion, nasal congestion, ocular itching, lacrimation, weight gain, sedation and additional methylprednisolone usage. All symptoms were scored on a 0-3 scale (0: absent; 1: mild; 2: moderate; 3: severe). A mean 8 points daily score during the previous week was required for recruitment. Nasal eosinophilia was determined at baseline and at the end of treatment. The study was conducted in may 1992. We did not find significant differences between the two groups, except in sneezes number and sedation. Both groups improved their symptoms, in comparison with the basal week (p < 0.01) and reduced their oral steroid use (p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Secciones de Alergología y Citopatología, Hospital Virgen de la Arrixaca, Murcia, España.
authors.forename: J
authors.initials: J
authors.lastname: Hernández
authors.forename: J M
authors.initials: JM
authors.lastname: Negro
authors.forename: A
authors.initials: A
authors.lastname: Pascual
authors.forename: J
authors.initials: J
authors.lastname: Sola
authors.forename: J C
authors.initials: JC
authors.lastname: Miralles
authors.forename: A
authors.initials: A
authors.lastname: Mora
authors.forename: J A
authors.initials: JA
authors.lastname: Pagán
authors.forename: F J
authors.initials: FJ
authors.lastname: García
authors.forename: J D
authors.initials: JD
authors.lastname: López
authors.forename: F
authors.initials: F
authors.lastname: Sarrió
mesh_terms: D000293:Adolescent; D000328:Adult; D017332:Cetirizine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004804:Eosinophils; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009093:Mucus / Q000166:cytology; D009296:Nasal Cavity; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012720:Severity of Illness Index; D012912:Sneezing / Q000187:drug effects; D016896:Treatment Outcome; D014851:Wakefulness / Q000187:drug effects
chemical_list: D008775:Methylprednisolone; D017332:Cetirizine
vernacular_title: Estudio comparativo entre 10 y 20 mg de cetirizina en el tratamiento sintomático de la rinoconjuntivitis alérgica estacional.